PeptiDream Inc.
11:30 AM - 11:45 AM (EDT), Thursday, June 8, 2023 ・ Session Room 104A
PeptiDream Inc. (Tokyo Stock Exchange: 4587) is leading the translation of macrocyclic peptides into a new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide.
Founded in 2006 and based in Kawasaki, Japan, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology, a versatile, state-of-the-art discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, to identify highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, peptide-drug conjugate (PDC) or multi-functional peptide conjugate (MPC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of partners driving the development of a broad, diverse pipeline.
PeptiDream also commercializes radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma.
Founded in 2006 and based in Kawasaki, Japan, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology, a versatile, state-of-the-art discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, to identify highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, peptide-drug conjugate (PDC) or multi-functional peptide conjugate (MPC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of partners driving the development of a broad, diverse pipeline.
PeptiDream also commercializes radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma.
Ticker:
4587
Exchange:
Tokyo Stock Exchange
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Kanagawa
Company HQ Country:
Japan
Year Founded:
2006
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
PD-L1 inhibitor
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
